Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis

Càncer de mama; Marcadors predictius; Pronòstic

Detalles Bibliográficos
Autores: O’Shaughnessy, Joyce, Cortés Castan, Javier, Goldstein, Lori J., Alexis, Karenza, Xie, Ran, Twelves, Chris
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Departament de Salut de la Generalitat de Catalunya (DS)
Repositorio:Scientia. Dipòsit d'Informació Digital del Departament de Salut
OAI Identifier:oai:scientiasalut.gencat.cat:11351/6269
Acceso en línea:https://hdl.handle.net/11351/6269
Access Level:acceso abierto
Palabra clave:Mama - Càncer - Tractament
Metàstasi
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
id ES_cd10fe9e43cf824be3e1d744c8e4da47
oai_identifier_str oai:scientiasalut.gencat.cat:11351/6269
network_acronym_str ES
network_name_str España
repository_id_str
spelling Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysisO’Shaughnessy, JoyceCortés Castan, JavierGoldstein, Lori J.Alexis, KarenzaXie, RanTwelves, ChrisMama - Càncer - TractamentMetàstasiDISEASES::Neoplasms::Neoplasms by Site::Breast NeoplasmsOther subheadings::Other subheadings::Other subheadings::/drug therapyDISEASES::Neoplasms::Neoplastic Processes::Neoplasm MetastasisENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mamaOtros calificadores::Otros calificadores::Otros calificadores::/farmacoterapiaENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásicaCàncer de mama; Marcadors predictius; PronòsticCáncer de mama; Marcadores predictivos; PronósticoBreast cancer; Predictive markers; PrognosisPrior pooled analysis of eribulin studies (301 and 305) indicated eribulin prolonged overall survival (OS) in patients with locally advanced/metastatic breast cancer (MBC) regardless of visceral or nonvisceral disease. This hypothesis-generating post hoc analysis examined the efficacy of eribulin according to the location of metastatic sites at baseline in 1864 pretreated patients with locally advanced/MBC from studies 301 and 305. Analyses included OS, progression-free survival (PFS), and objective response rate; OS and PFS were also analyzed according to estrogen-receptor status. Eribulin appeared efficacious in patients with locally advanced/MBC, irrespective of the location of metastases at baseline. A nominally significant difference in OS in favor of patients randomized to eribulin compared with control in patients with bone, lymph node, and chest wall/breast/skin metastases at baseline was observed. Additionally, a difference in OS was also seen in patients with liver metastases randomized to eribulin versus control (median: 13.4 versus 11.3 months, respectively; hazard ratio, 0.84 [95% CI: 0.72, 0.97]). Results of this exploratory analysis suggest that eribulin may be efficacious for the treatment of locally advanced/MBC for patients with bone, liver, lung, lymph node, and chest wall/breast/skin metastases.This study was funded by Eisai Inc., Woodcliff Lake, NJ. Medical writing support was provided by Jeffrey Bratz, PhD, Oxford PharmaGenesis, Newtown, PA, USA, and was funded by Eisai Inc., Woodcliff Lake, NJ, USA.Nature ResearchInstitut Català de la Salut[O'Shaughnessy J] Baylor University Medical Center, Texas Oncology and US Oncology, Dallas, TX, USA. [Cortes J] IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Twelves C] Leeds Institute of Medical Research at St James’s and Leeds Teaching Hospitals Trust, Leeds, UK. [Goldstein LJ] Fox Chase Cancer Center, Philadelphia, PA, USA. [Alexis K, Xie R] Eisai Inc., Woodclif Lake, NJ, USAVall d'Hebron Barcelona Hospital Campus202120212020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11351/6269Scientiareponame:Scientia. Dipòsit d'Informació Digital del Departament de Salutinstname:Departament de Salut de la Generalitat de Catalunya (DS)InglésScientific Reports;10https://doi.org/10.1038/s41598-020-66980-0Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:scientiasalut.gencat.cat:11351/62692026-06-12T09:38:37Z
dc.title.none.fl_str_mv Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis
title Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis
spellingShingle Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis
O’Shaughnessy, Joyce
Mama - Càncer - Tractament
Metàstasi
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
title_short Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis
title_full Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis
title_fullStr Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis
title_full_unstemmed Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis
title_sort Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis
dc.creator.none.fl_str_mv O’Shaughnessy, Joyce
Cortés Castan, Javier
Goldstein, Lori J.
Alexis, Karenza
Xie, Ran
Twelves, Chris
author O’Shaughnessy, Joyce
author_facet O’Shaughnessy, Joyce
Cortés Castan, Javier
Goldstein, Lori J.
Alexis, Karenza
Xie, Ran
Twelves, Chris
author_role author
author2 Cortés Castan, Javier
Goldstein, Lori J.
Alexis, Karenza
Xie, Ran
Twelves, Chris
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[O'Shaughnessy J] Baylor University Medical Center, Texas Oncology and US Oncology, Dallas, TX, USA. [Cortes J] IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Twelves C] Leeds Institute of Medical Research at St James’s and Leeds Teaching Hospitals Trust, Leeds, UK. [Goldstein LJ] Fox Chase Cancer Center, Philadelphia, PA, USA. [Alexis K, Xie R] Eisai Inc., Woodclif Lake, NJ, USA
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Mama - Càncer - Tractament
Metàstasi
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
topic Mama - Càncer - Tractament
Metàstasi
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
description Càncer de mama; Marcadors predictius; Pronòstic
publishDate 2020
dc.date.none.fl_str_mv 2020
2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/6269
url https://hdl.handle.net/11351/6269
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Scientific Reports;10
https://doi.org/10.1038/s41598-020-66980-0
dc.rights.none.fl_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Nature Research
publisher.none.fl_str_mv Nature Research
dc.source.none.fl_str_mv Scientia
reponame:Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname:Departament de Salut de la Generalitat de Catalunya (DS)
instname_str Departament de Salut de la Generalitat de Catalunya (DS)
reponame_str Scientia. Dipòsit d'Informació Digital del Departament de Salut
collection Scientia. Dipòsit d'Informació Digital del Departament de Salut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419776761135104
score 15.81155

Similares en LA Referencia